Fleckenstein A.: Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Annu Rev Pharmacol Toxicol17:149-166, 1977.
2.
Fleckenstein A.: Specific inhibitors and promotors of calcium action in the excitation-contraction coupling of heart muscle and their role in the prevention or production of myocardial lesions. In: Calcium and the Heart, ed. by Fleckenstein H, Opie LH, London, Academic Press , 1970.
3.
Haeusler G.: Differential effects of verapamil on excitation-contraction coupling in smooth muscle and on excitation-secretion coupling in adrenergic terminals. J Pharmacol Exp Ther180:672-679, 1972.
4.
Krikler D.: Verapamil in cardiology. Eur J Cardiol2:3-10, 1974.
5.
Singh BN, Ellrodt G., Peter CT: Verapamil: A review of its pharmacologic properties and therapeutic use. Drugs15:169-197, 1978.
6.
Henry PD: Calcium ion (Ca2+) antagonist: mechanism of action and clinical applications . Prac Cardiol5:1450-1456, 1979 .
7.
Ellrodt G., Chew Cyc, Singh BN: Therapeutic implications of slow channel blockade in cardiocirculatory disorders . Circulation62:669-679, 1980.
8.
Antman EM, Stone PH, Muller JE, Braunwald E.: Calcium channel blocking agents in the treatment of cardiovascular disorders: I. Basic and clinical electrophysiologic effects. Ann Intern Med93:875-885, 1980.
9.
Stone PH, Antman EM, Muller JE, Braunwald E.: Calcium channel blocking agents in the treatment of cardiovascular disorders: II. Hemodynamic and clinical applications. Ann Intern Med93:886-904, 1980.
10.
Hille B.: Ionic channels in excitable membranes: Current problems and biophysical approaches . Biophys J22:283-294, 1978.
11.
Almers W.: Gating currents and charge movements in excitable membranes. Rev Physiol Biochem Pharmacol82:96-190, 1978.
12.
Katz AM: Contractile proteins of the heart. Physiol Rev50:63-158, 1970.
13.
Langer GA: Heart: excitation-contraction coupling. Ann Rev Physiol35:55-86, 1973.
14.
Fabiato A., Fabiato F.: Calcium and cardiac excitation-contraction coupling. Ann Rev Physiol41:473-484, 1979.
15.
Adelstein RS : Hathaway DR: Role of calcium and cyclic adenosine 3':5' monophosphate in regulating smooth muscle contraction: Mechanisms of excitation-contraction coupling in smooth muscle. Am J Cardiol44:783-787, 1979.
16.
Henry PD: Chronotropic and inotropic effects of coronary vasodilators. In: Adalat: New Experimental and Clinical Results. Amsterdam , Excerpta Medica, 1979, pp. 3-4.
17.
Nayler WG, Szeto J.: Effect of verapamil on contractility oxygen utilization, and calcium exchange ability in mammalion heart muscle. Cardiovasc Res6:120-128, 1972.
18.
Nakajima H. , Hoshiyana M., Yamashita K., Kiyomoto A.: Effect of diltiazem on electrical and mechanical activity of isolated cardiac ventricular muscle of guinea pig. Jpn J Pharmacol25:383-392, 1975.
19.
Mangiardi LM , Hariman RJ, McAllister RG Jr, et al: Electrophysiologic and hemodynamic effects of verapamil correlation with plasma drug concentrations. Circulation57:366-372, 1978.
20.
Refsum H., Landmark K.: The effects of a calcium antagonistic drug, nifedipine, on the mechanical and electrical activity of the isolated rat atrium. Acta Pharmacol Toxicol37:369-376, 1975.
21.
Mannhold R. , Steiner R., Haas W., Kaufmann R.: Investigations on the structure-activity relationships of verapamil. Naunyn Schmiedebergs Arch Pharmacol310:69-78, 1979.
22.
Lydtin H., Lohmoller R., Schmitz H., Walter I.: Hemodynamic studies on Adalat in healthy volunteers and in patients. In: Second International Adalat Symposium: New Therapy of Ischemic Heart Disease, ed. by Lochner W, Braasch W, Kroneberg G.Berlin, Excerpta Medica, 1975, pp. 112-123.
23.
Lichtlen H., Engel J., Wolf R., Amende I.: The effect of the calcium antagonistic drug nifedipine on coronary and left ventricular dynamic in patients with coronary heart disease. In: Calcium Antagonismus, ed. by Fleckenstein A, Roskamm H.Heidelberg , Springer -Verlag, 1980, pp. 270-281.
24.
Lynch P., Dangie H., Krikler S., Krikler D.: Objective assessment of anti-anginal treatment:A double-blind comparison of propranolol, nifedipine, and their combination. Br Med J280:184-187, 1980.
25.
Anastassiades CJ: Nifedipine and beta-blocking drugs. Br Med J281:1251-1252, 1981.
26.
Opie LH, White DA: Adverse interaction between nifedipine and B-blockade. Br Med J281:1462, 1981.
27.
Vincenzi M. , Allegri P., Gabaldo S., et al: Comparison of hemodynamic effects caused by I.V. administration of verapamil in healthy subjects. Arzneim Forsch26:1221-1223, 1976.
28.
Atterhog JH , Ekelund LG: Hemodynamic effects of intravenous verapamil at rest and during exercise in subjectively healthy middle-aged men. Eur J Clin Pharmacol8:317-322, 1975.
29.
Lewis BS, Mitha AS, Gotsman MS: Immediate hemodynamic effects of verapamil in man. Cardiology60:366-376, 1975.
30.
Ryden L., Saetre H.: The hemodynamic effect of verapamil. Eur J Clin Pharmacol3:153-156, 1971.
31.
Ross G., Jorgensen CR: Cardiovascular action of iproveratril. J Pharmacol Exp Ther158:504-509, 1967.
32.
Nayler WG, McInnes I., Swann JB, et al: Some effects of iproveratril (Isoptin) on the cardiovascular system. J Pharmacol Exp Ther161:247-261, 1968.
33.
Angus JA, Dhumma-Upahorn P., Cobbun LB, Goodman AH: Cardiovascular action of verapamil in the dog with particular reference to myocardial contractility and atrioventricular conduction. Cardiovasc Res10:623-632, 1976.
34.
Singh BN, Roche Ahg: Effects of intravenous verapamil on hemodynamics in patients with heart disease . Am Heart J94:593-599, 1977.
35.
Ferlinz J., Easthope J., Aronow WS: Effects of verapamil on myocardial performance in coronary disease. Circulation59:313-319, 1979.
36.
Rackley CE: Quantitative evaluation of left ventricular function by radiographic techniques . Circulation54:862-879, 1976.
37.
Chew Cyc, Hecht HS, Collett JT, et al: Influence of severity of ventricular dysfunction on hemodynamic responses to intravenously administered verapamil in ischemic heart disease . Am J Cardiol47:917-922, 1981.
38.
Benalm ME: Asystole after verapamil. Br Med J2:169-170, 1972.
39.
Boothby GB, Garrard CS, Pickering D.: Intravenous verapamil in cardiac arrhythmias. Br Med J2:349, 1972.
40.
Seabra-Gomes R., Richards A., Sutton R.: Hemodynamic effects of verapamil and practolol in man. Eur J Cardiol4:79-85, 1976.
41.
Leon MB, Rosing DR, Bonow RO, et al: Clinical efficacy of verapamil alone and combined with propranolol in treating patients with chronic stable angina pectoria. Am J Cardiol48:131-139, 1981.
42.
Bowles M., Subramanian V., Davies AB, Raftery EB: Comparison of the antianginal action of verapamil and propranolol. Br Med J282:1754, 1981.
43.
Kieval J., Kirsten EB, Kessler KM, et al: The effects of intravenous verapamil on hemodynamic status of patients with coronary artery disease receiving propranolol. Circulation65:653-659, 1982.
44.
Kinoshita M. , Motomura M., Kusukawa R., Kawakita S.: Comparison of hemodynamic effects between B-blocking agents and a new antianginal agent, diltiazem hydrochloride. JpnCirculation J 43:587-598, 1979.
45.
Kusukawa R. , Kinoshita M., Shimono Y., et al:Hemodynamic effects of a new antianginal drug, diltiazem hydrochloride. Arznein Forsch27:878-887, 1977.
